Edmond DE Rothschild Holding S.A. Buys New Position in Nurix Therapeutics, Inc. $NRIX

Edmond DE Rothschild Holding S.A. bought a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, HoldingsChannel.com reports. The fund bought 90,000 shares of the company’s stock, valued at approximately $2,183,000.

Several other hedge funds also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Nurix Therapeutics during the second quarter valued at approximately $212,769,000. Vanguard Group Inc. grew its stake in Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after acquiring an additional 1,460,736 shares during the period. General Atlantic L.P. purchased a new stake in Nurix Therapeutics in the 4th quarter worth approximately $92,899,000. Morgan Stanley raised its holdings in Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after acquiring an additional 2,620,323 shares during the last quarter. Finally, Vestal Point Capital LP raised its holdings in Nurix Therapeutics by 35.0% in the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock valued at $88,969,000 after acquiring an additional 1,215,000 shares during the last quarter.

Nurix Therapeutics Trading Down 2.7%

NRIX stock opened at $27.05 on Friday. The company has a market cap of $2.81 billion, a PE ratio of -7.84 and a beta of 1.79. The stock has a 50-day moving average price of $23.24 and a two-hundred day moving average price of $18.59. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NRIX has been the topic of several analyst reports. Wall Street Zen upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Jefferies Financial Group upped their target price on Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Truist Financial increased their target price on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Robert W. Baird lifted their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. Finally, UBS Group upped their price objective on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.21.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total transaction of $108,900.00. Following the sale, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 25,314 shares of company stock valued at $589,361. Corporate insiders own 6.70% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.